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ABSTRACT 
 
Guillain-Barré syndrome (GBS) is considered to have an immune-mediated basis, but 
the genetic contribution to GBS is unclear. We conducted a GWAS involving 215 
GBS patients and 1,105 healthy controls. No significant associations of individual 
SNPs or imputed HLA types were observed. We performed a genome-wide complex 
trait analysis for evaluation of the heritability of GBS, and found that common SNPs 
contribute up to 25% of susceptibility to the disease. Genetic risk score analysis 
showed no evidence of overlap in genetic susceptibility factors of GBS and multiple 
sclerosis. Given the unexplained heritability of the trait further larger GWAS are 
indicated. 
 
KEYWORDS: Guillain-Barré syndrome; case-control study; genome-wide 
association study; heritability; genetic risk score; human leukocyte antigen (HLA) 
genes. 
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1. INTRODUCTION 
 
Guillain-Barré syndrome (GBS) is a severe acute ascending peripheral neuropathy 
causing weakness of the limbs. GBS with weakness can be subdivided into acute 
inflammatory demyelinating polyradiculoneuropathy (AIDP), acute motor axonal 
neuropathy (AMAN), and acute motor and sensory axonal neuropathy (AMSAN). 
There are also disorders that are regarded as GBS variants, such as Miller Fisher 
syndrome (MFS) or focal variants of GBS; [1]. The pathogenesis of GBS is 
incompletely understood. It is considered to be mediated by immune-mediated 
responses, triggered by infection, with two-thirds of patients experiencing a preceding 
bacterial or viral infection [2, 3]. However, unlike classical autoimmune diseases, 
GBS is typically monophasic, and is more common in males, and does not have a 
clear HLA association, as required by the Rose and Bona criteria for autoimmune 
diseases [4].  
  
GBS has pathological similarities to multiple sclerosis (MS), another inflammatory 
demyelinating neurological disease. However, in MS the central rather than peripheral 
nervous system is targeted [5]. MS is a highly heritable disease, found to be 
associated with more than 140 genetic variants [6]. A potential genetic basis for GBS, 
however, is less clear. No systematic twin study has been performed. Increased 
familiality of the disease has been reported, as well as evidence of anticipation with 
younger generations developing disease at an earlier age, suggesting a genetic 
mechanism [7-10]. 
 
Many candidate gene studies have been performed in GBS, most focusing on human 
leukocyte antigen (HLA) genes, the most important genetic regulators of the immune 
system, as well as other genes [11]. HLA genes are encoded within the Major 
Histocompatibility Complex (MHC), a highly polymorphic region that is essential in 
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the regulation of immunity and infection, and is closely linked with most autoimmune 
diseases [12]. However, to date, most studies of HLA associations with GBS have 
been negative [13-15], with no positive findings being consistently replicated between 
studies. A recent meta-analysis has suggested association of TNF genetic variants 
with disease, but this locus is known to be markedly affected by population 
stratification, which was not controlled for in the meta-analysis [16].  Similarly, 
multiple association studies of non-MHC candidate genes have been reported but 
none has achieved definitive levels of association, nor been consistently replicated. 
None of these studies has controlled for population stratification, and all have been 
modest in size. Therefore, we conducted the present genome-wide association study 
(GWAS) to explore the possible genetic basis of GBS more extensively. 
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2. METHODS 
 
2.1 Demographics  
A total of 215 patients with confirmed diagnosis of GBS were included in our study 
(Table 1). GBS was defined according to the National Institute of Neurological 
Disorders and Stroke criteria [17], and the majority of patients had level 1 or level 2 
certainty of diagnosis according to the Brighton criteria [18](Table 1). 1,105 samples 
were collected as control group. All samples came from centres in Brisbane, 
Townsville, Sunshine Coast and Sydney, Australia. Both case and control subjects 
were of Caucasian ethnicity. Informed written consent was obtained from all 
participants. This study was approved by the Human Research Ethics Committee of 
the Royal Brisbane and Women's Hospital (approval number HREC/QRBW/31). 
 
2.2 Quality control and association analysis 
Genotyping was performed in an ISO15189-accredited clinical genomics facility, 
Australian Translational Genomics Centre (ATGC), Queensland University of 
Technology. All samples were genotyped by Illumina HumanOmniExpress 
(OmniExpress) BeadChip. Quality control (QC) was performed using the PLINK 1.9 
package (https://www.cog-genomics.org/plink2)[19, 20] and Shellfish 
(http://www.stats.ox.ac.uk/~davison/software/shellfish). Detailed information 
regarding QC filtering is described below (Table 2). We included all 22 autosomal 
chromosomes in our study. For individuals, samples with a missing genotype rate 
higher than 10% or extreme heterozygosity (±3SD from the mean) were excluded. 
Pairwise identity by descent (IBD) was used to detect cryptic relatedness, with 
samples with an IBD > 0.185 excluded from further analysis. For markers, SNPs with 
a call rate less than 95% or with significant differences (P < 10−5) in missing genotype 
rate between cases and controls were removed. SNPs identified with extensive 
deviation (P < 10−6) from Hardy-Weinberg equilibrium (HWE) and minor allele 
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frequency (MAF) of <5% were excluded. Differential ethnicity was detected by 
principal component analysis (PCA) using Shellfish (Supplementary Figure S1). After 
merging with HapMap genotypes, samples not clearly consistent with a Caucasian 
ethnicity were excluded. Then a second PCA was conducted to identify outliers, 
defined as more than ±6SD from the mean for the first principal component, to correct 
for population stratification. After QC steps were performed, the genotype-phenotype 
association was tested using logistic regression analysis with the first principal 
component as the covariant using PLINK. Genomic inflation was assessed by 
quantile-quantile (Q-Q) plot and the genomic inflation factor, λ1000.  
 
2.3 Imputation of SNPs in the human leukocyte antigen region 
SNPs in the HLA region were specifically imputed by the SNP2HLA software [21], 
with The National Institute of Diabetes and Digestive and Kidney Diseases Type 1 
Diabetes Genetics consortium dataset 
(https://www.niddkrepository.org/studies/t1dgc/) used as the reference panel. The 
logistic regression analysis was performed with dosage data after removing poorly 
imputed markers and sample outliers. All analyses were performed following the 
standard procedures according to the SNP2HLA instructions 
(http://broadinstitute.rog/mpg/snp2hla/).  
 
2.4 Estimation of the narrow-sense heritability (h2) 
Genome-wide Complex Trait Analysis (GCTA) was applied to estimate the variance 
explained by all the SNPs [22]. Since we were conducting a case-control study, we 
performed a further, more stringent, QC for this analysis. Markers with a call rate < 
95%, or individuals with a genotype missing rate > 1%, were excluded, and 0.05 was 
chosen as the cutoff for IBD and the P-value for HWE [23]. Genetic relationship 
matrix (GRM) from all autosomal SNPs was assessed to remove samples with cryptic 
relatedness (0.025 as the cutoff value), followed by h2 estimation. 
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2.5 Genetic risk score test 
A genetic risk score (GRS) test was performed with a set of genome-wide significant 
multiple sclerosis (MS)-associated SNPs. From published MS studies in the 
NHGRI-EBI GWAS catalog [24], we selected a set of SNPs that reached 
genome-wide significance for association with MS (P < 5 × 10−8; 49 SNPs at the time 
of analysis), and compared the allele frequency of these SNPs between cases and 
controls in our GBS study using both unweighted and weighted genetic risk scores. 
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3. RESULTS 
We started with genotype data of 1,320 individuals (215 cases and 1,105 controls) and 
699,609 SNPs. After QC, 830 individuals (191 cases and 639 controls) and 579,499 
SNPs remained. As shown in the quantile-quantile plot (Supplementary Figure S2), 
the inflation factor was in the acceptable range, with λ1000 = 1.056 when correcting for 
one principal component. No SNPs reached the suggestive association threshold (P < 
10−5). The three most associated SNPs were rs9371600 (chromosome 6q25, P = 1.56 
× 10−5), rs16904331 (chromosome 8q24; P = 1.65 × 10−5) and rs2243523 
(chromosome 17q25; P = 1.906 × 10−5; Figure 1). Detailed information for the top 
five associated SNPs is shown in Table 3. Considering directly genotyped SNPs, the 
strongest MHC association was with SNP rs1264622 (P = 4.37 × 10−3). 
 
3.1 Imputation of HLA genes 
Given the previous reported associations of GBS with HLA alleles, we investigated 
these and the MHC region more closely. A total of 8,961 SNPs within the MHC 
region, HLA alleles and their composite amino acids were imputed with SNP2HLA. 
We excluded markers with r2 < 0.5 and samples with unreliable imputed data, leaving 
8,597 SNPs and 821 individuals for further logistic regression analysis. No MHC 
SNPs or imputed HLA alleles reached suggestive significance levels for association 
with GBS. The strongest SNP association with rs6928738 (P = 2.19 × 10−4; within 
the MHC Class I region, nearest gene being the hypothetical gene, LOC646570). The 
strongest HLA association was with HLA-A*3001 (P = 1.29 × 10−2). A recent 
meta-analysis suggested that a polymorphism in the TNFA promoter (TNF-α 308G/A, 
rs1800629, risk allele=A) was associated with GBS .  This association was restricted 
to Asian studies with no association observed in Caucasians, and was only seen with 
comparison of AA vs GG genotypes or a dominant model (AA vs AG+GG) [16].  
No association was observed with allelic analysis (A vs G), or the typical comparison 
of genotype counts (AA/AG/GG in cases vs controls).  In the current study, nominal 
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association was seen with a recessive model (P=0.031) and comparison of AA vs GG 
genotypes (P=0.027) but no association was seen with either dominant (P=0.23), 
genotypic (P=0.076) or allelic models (OR= 1.3, risk allele=A, P = 0.076). 
 
3.2 Estimation of the heritability of Guillain-Barré syndrome 
As we were unable to identify any variants that were associated with GBS at a 
genome-wide level of significance, we employed GCTA to estimate the genetic 
influence on risk of the disease. After filtering with the more stringent QC steps 
required for case-control studies, 756 individuals and 544,077 SNPs were available 
for subsequent analysis. h2 estimates were calculated for a range of GBS prevalences 
(Figure 2). This showed that h2 captured by these SNPs was ≥0.15 for prevalences 
>1/10,000. 
 
3.3 There is no evidence of a shared genetic basis between Guillain-Barré 
syndrome and multiple sclerosis  
Since GBS and MS have pathological similarities, we sought to determine whether 
there was a potential shared genetic basis between the two diseases. Therefore, we 
conducted a GRS test for GBS with a set of MS-associated SNPs with genome-wide 
significance. A 49-locus genetic risk score derived from MS studies (Supplementary 
Table S1) was applied in our dataset for allele frequency calculation. No difference (P 
< 0.05) was observed between case and control groups using either a weighted or 
unweighted score (data not shown).  
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4. DISCUSSION  
 
GBS is regarded as an immune-mediated inflammatory demyelinating disease, and a 
number of previous studies have suggested an association with HLA alleles, and with 
other candidate genes. However, the involvement of candidate genes in the 
development and severity of GBS has remained contentious. To the best of our 
knowledge, this is the first GWAS studying GBS, and no variants were identified that 
reached genome-wide significance. What is perhaps most striking from this GWAS, 
was the lack of any association between MHC SNPS or HLA alleles and GBS.  
 
Recent candidate gene association studies of HLA alleles and GBS have yielded 
varying results. A study on Iraqi cases and controls found that the frequencies of the 
HLA genotypes, HLA-DRB4*01:01, HLA-DRB1*03:01 and HLA-DRB1*07:01, were 
significantly increased in GBS patients [25]. nother study in Tunisians showed an 
increased prevalence of HLA-DRB1*13 and HLA-DRB1*14 and a decreased 
prevalence of HLA-DRB1*03 and HLA-DRB1*07 in GBS patients [26]. A study from 
Mexico found HLA-DR3 was significantly increased in GBS patients [27]. A recent 
meta-analysis was unable to find any association with HLA-DQB1 alleles in 
Caucasian GBS patients [28], consistent with individual studies finding no HLA Class 
II associations with GBS [29] When considering different GBS subtypes, two studies 
of Chinese GBS patients found that epitopes of HLA-DQB1 amino acids, and the 
allele HLA-DRB1*13, were associated with AIDP compared to AMAN [30, 31]. 
Furthermore, a study of Indian cases and controls reported that HLA-DRB1*0701 was 
associated with GBS patients who had preceding infection [32]. In relation to HLA 
class I genes, Blum et al. [33] performed a study on killer cell immunoglobulin-like 
receptors (KIRs), molecules involved in the innate immune response, and their HLA 
ligands. They found that patients with GBS were more likely than controls to have 
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HLA-C2 and HLA-B Bw4 HLA Class I allele groups, which are essential in 
interactions with KIRs [33].  
 
Although no SNPs with genome-wide or suggestive significance were revealed in the 
current study, we investigated the most strongly associated SNPs further. The most 
strongly associated SNP in our study was rs9371600, located in SYNE1 on 
chromosome 6. SYNE1 encodes a spectrin repeat-containing protein that localizes to 
the nuclear membrane. SYNE1 is expressed in multiple tissues, including the central 
nervous system and skeletal muscle [34]. SYNE1 mutations have been implicated in a 
number of diseases, including Emery-Dreifuss muscular dystrophy [35], 
spinocerebellar ataxia [36] and autosomal recessive arthrogryposis [37], and were 
observed in a family with two siblings with intellectual disability, spastic paraplegia, 
axon neuropathy and leukoencephalopathy [38]. As our GWAS cases included all 
GBS subtypes, including a few cases of MFS in which patients manifest ataxia, it is 
possible that the signal for rs9371600 was lessened by other GBS subtypes, and 
further investigation is warranted. 
 
The next most significant SNP, rs16904331, was nominally protective for GBS, and is 
located in an intergenic region on chromosome 8. The closest gene to this SNP, 
ADCY8, encodes a membrane-bound adenylate cyclase. ADCY8 is associated with 
post-traumatic stress disorder, bipolar disorder and alcohol dependence comorbid 
with depression in females [39]. Chang et al. [40] performed a genome-wide 
expression analysis of peripheral leukocytes of GBS patients to identify 
GBS-associated signaling pathways. The top five SNPs identified in the present study 
were not among the differentially expressed genes in GBS patients. However, ADCY7 
was up-regulated in GBS patients, and featured among six of the ten canonical 
pathways identified in the gene-expression analysis [40]. ADCY7 is an adenylate 
cyclase like ADCY8, the closest gene to the nominally protective variant, rs16904331, 
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identified here. An ADCY7 variant doubles the risk of ulcerative colitis [41], and a 
possible link between GBS and ulcerative colitis has already been suggested [42, 43], 
although a causal relationship remains speculative.  
 
Association has previously been reported in a meta-analysis between the TNF-308 
SNP and GBS [16].  This association was only observed in comparison of the AA 
and GG genotypes, only in Asians and not in Caucasians, and not in allelic analyses.  
On further inspection of the pooled studies, the association is driven by the findings of 
one Chinese study [44], for which the genotypes overall are not in HWE 
(P=4.06x10-12), raising concerns about genotyping accuracy. In the current study we 
see no association of this variant with GBS, although we cannot exclude association 
with a variant of small-moderate effect size. 
 
Our study had some limitations. A key issue is the sample size which is too small to 
identify other than large genetic effects. Although our study with 215 cases is larger 
than most previous GBS studies, its power was still modest. Under the assumption of 
a prevalence of approximately 1/10,000, we estimated that we achieved power of 
19.6% to detect loci with a MAF = 0.4, additive odds ratio of 1.5, D´ of 1.0 (linkage 
disequilibrium) and genome-wide significance threshold of P < 5 × 10−8 [45]. Using 
the same assumptions regarding the genetic model, we estimate that the study had 
80% power to detect association with an additive odds ratio of 2.5, and for an additive 
odds ratio of 2.0 at suggestive levels of association (P < 10−5).  As such, a larger 
cohort achieved from an international collaboration or meta-analysis might be the 
only way to achieve the required statistical power. Secondly, GBS can be divided into 
subtypes based on clinical and electrophysiological findings, and the proportions of 
different subtypes of GBS vary greatly by geography [46]. For the patients with 
AIDP, the pathology is of inflammation and demyelination, whereas in AMAN there 
is less inflammation and antibody mediated mechanisms are proposed. For the GBS 
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variants such as MFS and the focal variants, the pathology is also possibly antibody 
mediated. Thus, multiple mechanisms may lead to GBS, with different immunologic 
pathways involved among GBS subtypes. In the current study, patients with different 
GBS subtypes were analysed together. When larger cohorts are available in the future, 
it will be necessary to conduct analyses on different subtypes.  
 
Our data also suggests that common variant heritability of GBS is low, and therefore 
that most of the risk of developing GBS is either environmental or due to genetic 
variants not captured (i.e. directly genotyped or in linkage disequilibrium with 
genotyped SNPs) using the SNP microarray employed here. So far, no definite 
prevalence data of GBS have been published, and the incidence of GBS was reported 
to be 1.1-1.8/100,000 per year [47]. Our study shows that even assuming a prevalence 
or lifetime risk of GBS as high as 2.5/10,000 or greater the common variant 
heritability of the condition remains <0.25. It may be that using denser SNP coverage 
and including SNPs with lower MAF that a higher heritability would be 
demonstrated, but to identify such variants would also require much larger studies. 
We also cannot exclude the possibility that rare SNPs, copy number variants, or 
heritable epigenetic variants not tagged by the SNPs studied, contribute to GBS 
pathogenesis. 
 
GRS analysis can be used for disease risk prediction and to investigate the genetic 
relatedness between different diseases. In this study, we used GRS to investigate the 
potential aetiopathogenic relatedness of MS and GBS. Regardless of the algorithm 
used, whether or not weighted by their effect sizes [48]), GRS based on known 
MS-associated SNPs did not discriminate between GBS cases and controls. This 
suggests that although these two diseases are clearly primarily immune mediated and 
target overlapping components of the nervous system, their aetiopathogeneses are 
likely to be different.  
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5. CONCLUSIONS 
We report the first GWA-based study on GBS. We did not find any risk loci to GBS 
susceptibility with genome-wide levels of significance or genetic relatedness with 
another immune-mediated disease with nervous system lesions. This supports the 
view of previous studies that indicated HLA is not a critical risk factor for GBS 
pathogenesis. We demonstrate that up to 25% of susceptibility to GBS is determined 
by common genetic variants. Further larger studies are required, which may also 
enable the genetic variants associated with specific subsets of GBS to be teased apart. 
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Table 1. Patient characteristics. 
Patient Characteristica  Number 
Gender Male 
Female 
135 
80 
Brighton Criteria 
Diagnostic Certainty 
Level 1                   
Level 2                   
Level 3                             
Level 4                   
68 
107 
20 
20 
Hughes GBS Disability 
Scaleb 
1 
2 
3 
4 
5 
6 
2 
22 
35 
89 
43 
0 
GBS Subtype AIDP  
GBS, unspecified 
AMAN 
MFS 
Other subtypes 
105 
73 
8 
17 
12 
  
aThe median age of onset was 55.4 years of age, range 15.4–89.1 (data was available 
for 212 of the 215 patients). 
bHughes scale information was available for 191 of the 215 patients. 
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Table 2. Detailed information for quality control filtering. 
 Individuals or Markers remaining after each 
QC-filtering step (n) 
 Cases Controls Markers 
Before QC 215 1,105 699,609 
MIND < 0.1 215 1,102 − 
 
GENO < 0.05 − 
 
− 695,656 
HWE > 10−6 − − 693,288 
MAF > 0.05 − − 581,413 
Different missing rate between 
groups 
− − 579,499 
IBD < 0.185 204 798 − 
Heterozygosity (mean±3SD) 
with MIND < 0.1 
199 756 − 
PCA 191 639 − 
Final data for association 
analysis 
191 639 579,499 
 
GENO, missing rate per SNP; HWE, Hardy-Weinberg equilibrium; IBD, identity by 
descent; MAF, minor allele frequency; MIND, missingness per individual; n, number; 
PCA, principal component analysis; QC, quality control; SD, standard deviation. 
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Table 3. Detailed information of the five most significant SNPs. 
 
Chr, chromosome; OR, odds ratio. 
 
  
SNP Chr Position Locus/closest 
gene 
Minor 
allele 
OR P-value 
rs9371600 6 152790533 SYNE1 A 1.83 1.56 × 10−5 
rs16904331 8 131651760 ADCY8 G 0.33 1.65 × 10−5 
rs2243523 17 80680449 FN3KRP T 1.70 1.91 × 10−5 
rs7733891 5 75099610 POC5 G 2.66 1.96 × 10−5 
rs10506873 12 82792942 METTL25 G 2.23 1.99 × 10−5 
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FIGURE LEGENDS 
Figure 1. Manhattan plot of SNP associations with GBS. Blue line, P = 10−5; red line, 
P = 5 × 10−8. 
Figure 2. Estimated common-variant SNP heritability of GBS in relation to disease 
prevalence, with 95% confidence intervals indicated by vertical bars. 
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HIGHLIGHTS 
 
 Guillain-Barré syndrome (GBS) is considered to have an autoimmune basis. 
 A genetic contribution to GBS has been controversial, thus we performed a 
GWAS. 
 No single genetic variant (neither tagged nor imputed SNP) was associated with 
GBS 
 Common genetic variants contribute up to 25% of susceptibility to GBS. 
 No overlap in genetic susceptibility factors of GBS and multiple sclerosis. 
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